4mrd: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
==Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule==
==Crystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule==
<StructureSection load='4mrd' size='340' side='right' caption='[[4mrd]], [[Resolution|resolution]] 2.55&Aring;' scene=''>
<StructureSection load='4mrd' size='340' side='right' caption='[[4mrd]], [[Resolution|resolution]] 2.55&Aring;' scene=''>
Line 6: Line 7:
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4mre|4mre]], [[4mrf|4mrf]], [[4mrg|4mrg]], [[4mrh|4mrh]], [[4np3|4np3]], [[4np2|4np2]]</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4mre|4mre]], [[4mrf|4mrf]], [[4mrg|4mrg]], [[4mrh|4mrh]], [[4np3|4np3]], [[4np2|4np2]]</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Cd44, Cd44 Ly-24, Ly-24 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Cd44, Cd44 Ly-24, Ly-24 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mrd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mrd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mrd RCSB], [http://www.ebi.ac.uk/pdbsum/4mrd PDBsum]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mrd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mrd OCA], [http://pdbe.org/4mrd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4mrd RCSB], [http://www.ebi.ac.uk/pdbsum/4mrd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4mrd ProSAT]</span></td></tr>
</table>
</table>
== Function ==
== Function ==
Line 18: Line 19:
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
<div class="pdbe-citations 4mrd" style="background-color:#fffaf0;"></div>
==See Also==
*[[CD44|CD44]]
== References ==
== References ==
<references/>
<references/>

Revision as of 21:07, 11 August 2016

Crystal structure of the murine cd44 hyaluronan binding domain complex with a small moleculeCrystal structure of the murine cd44 hyaluronan binding domain complex with a small molecule

Structural highlights

4mrd is a 1 chain structure with sequence from Lk3 transgenic mice. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:, ,
Gene:Cd44, Cd44 Ly-24, Ly-24 (LK3 transgenic mice)
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

[CD44_MOUSE] Main cell surface receptor for hyaluronate. Adhesion to mucosal high endothelial venule and to types I and VI collagen. Probably involved in matrix adhesion, lymphocyte activation and lymph node homing.

Publication Abstract from PubMed

Selective inhibitors of hyaluronan (HA) binding to the cell surface receptor CD44 will have value as probes of CD44-mediated signaling and have potential as therapeutic agents in chronic inflammation, cardiovascular disease, and cancer. Using biophysical binding assays, fragment screening, and crystallographic characterization of complexes with the CD44 HA binding domain, we have discovered an inducible pocket adjacent to the HA binding groove into which small molecules may bind. Iterations of fragment combination and structure-driven design have allowed identification of a series of 1,2,3,4-tetrahydroisoquinolines as the first nonglycosidic inhibitors of the CD44-HA interaction. The affinity of these molecules for the CD44 HA binding domain parallels their ability to interfere with CD44 binding to polymeric HA in vitro. X-ray crystallographic complexes of lead compounds are described and compared to a new complex with a short HA tetrasaccharide, to establish the tetrahydroisoquinoline pharmacophore as an attractive starting point for lead optimization.

Fragment-Based Identification of an Inducible Binding Site on Cell Surface Receptor CD44 for the Design of Protein-Carbohydrate Interaction Inhibitors.,Liu LK, Finzel BC J Med Chem. 2014 Mar 27;57(6):2714-25. doi: 10.1021/jm5000276. Epub 2014 Mar 7. PMID:24606063[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Liu LK, Finzel BC. Fragment-Based Identification of an Inducible Binding Site on Cell Surface Receptor CD44 for the Design of Protein-Carbohydrate Interaction Inhibitors. J Med Chem. 2014 Mar 27;57(6):2714-25. doi: 10.1021/jm5000276. Epub 2014 Mar 7. PMID:24606063 doi:http://dx.doi.org/10.1021/jm5000276

4mrd, resolution 2.55Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA